WO1995003054A1 - Methods of treating apoptosis and associated conditions - Google Patents
Methods of treating apoptosis and associated conditions Download PDFInfo
- Publication number
- WO1995003054A1 WO1995003054A1 PCT/US1994/008268 US9408268W WO9503054A1 WO 1995003054 A1 WO1995003054 A1 WO 1995003054A1 US 9408268 W US9408268 W US 9408268W WO 9503054 A1 WO9503054 A1 WO 9503054A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dioxopiperazine
- apoptosis
- bis
- apoptotic
- cells
- Prior art date
Links
- 230000006907 apoptotic process Effects 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims abstract description 33
- JTHRRMFZHSDGNJ-UHFFFAOYSA-N piperazine-2,3-dione Chemical compound O=C1NCCNC1=O JTHRRMFZHSDGNJ-UHFFFAOYSA-N 0.000 claims abstract description 60
- 230000001640 apoptogenic effect Effects 0.000 claims description 15
- 208000010125 myocardial infarction Diseases 0.000 claims description 11
- 230000001154 acute effect Effects 0.000 claims description 7
- 206010061216 Infarction Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 230000007574 infarction Effects 0.000 claims description 6
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 208000028867 ischemia Diseases 0.000 claims description 5
- 210000004165 myocardium Anatomy 0.000 claims description 5
- -1 1-methyl-1,2-ethanediyl Chemical group 0.000 claims description 4
- 206010063837 Reperfusion injury Diseases 0.000 claims description 4
- CYJAWBVQRMVFEO-UHFFFAOYSA-N piperazine-2,6-dione Chemical compound O=C1CNCC(=O)N1 CYJAWBVQRMVFEO-UHFFFAOYSA-N 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 210000004351 coronary vessel Anatomy 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 230000001052 transient effect Effects 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 206010019196 Head injury Diseases 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 206010033799 Paralysis Diseases 0.000 claims description 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000001848 dysentery Diseases 0.000 claims description 2
- 230000007365 immunoregulation Effects 0.000 claims description 2
- 201000006370 kidney failure Diseases 0.000 claims description 2
- 230000003387 muscular Effects 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 206010052895 Coronary artery insufficiency Diseases 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 231100000417 nephrotoxicity Toxicity 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 60
- 238000003556 assay Methods 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 9
- 238000005259 measurement Methods 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 206010028851 Necrosis Diseases 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000017074 necrotic cell death Effects 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 230000002424 anti-apoptotic effect Effects 0.000 description 5
- 229940034982 antineoplastic agent Drugs 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 235000019833 protease Nutrition 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 230000006909 anti-apoptosis Effects 0.000 description 4
- 230000000118 anti-neoplastic effect Effects 0.000 description 4
- 239000012888 bovine serum Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000003359 percent control normalization Methods 0.000 description 4
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 238000003782 apoptosis assay Methods 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 206010064912 Malignant transformation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 229960000605 dexrazoxane Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000036212 malign transformation Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010062542 Arterial insufficiency Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 231100000457 cardiotoxic Toxicity 0.000 description 1
- 230000001451 cardiotoxic effect Effects 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007878 drug screening assay Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003426 interchromosomal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007925 intracardiac injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention is directed to methods to treat medical conditions associated with acute, undesirable apoptotic cell death in tissues and organs.
- necrosis is the traumatic destruction of cells leading to the release into the surrounding tissues of enzymes and intact DNA, which is then broken into random fragments. Unlike necrosis, apoptosis is a normal physiologic process that determines individual cell death and ultimate deletion of the cell from tissue. Apoptosis is an atraumatic, orderly, predictable dismantling of cells in which they shrink within their membranes while still in place in the tissue, and their DNA is packaged into nucleosomes for safe removal by white blood cells. Apoptotic cell death is characterized by cellular shrinkage, chromatin condensation, cytoplasmic blebbing, increased membrane permeability and interchromosomal DNA cleavage.
- Apoptosis is involved in a variety of normal and pathogenic biological events and can be induced by a number of unrelated stimuli. Changes in the biological regulation of apoptosis also occur during aging and are responsible for many of the conditions and diseases related to aging. Recent studies of apoptosis have implied that a common metabolic pathway leading to cell death may be initiated by a wide variety of signals, including changes in hormone levels, serum growth factor deprivation, chemotherapeutic agents, and ionizing radiation. Wyllie (1980) Nature, 284:555-556; Kanter et al. (1984) Biochem. Biophys. Res.
- the present invention is directed to methods of reversibly inhibiting apoptotic cell death associated with acute medical conditions.
- the methods comprise administering to a subject an amount of a therapeutically effective dioxopiperazine such as dexrazoxane, (DZR, ICRF187) sufficient to prevent or delay the appearance of apoptotic cell death.
- a therapeutically effective dioxopiperazine such as dexrazoxane, (DZR, ICRF187
- Figure 1 is a graph depicting the effects of dioxopiperazine on apoptosis as determined by the C3H- 10 model.
- the X axis of Figure 1 is presented in the log bis (dioxopiperazine) concentration. The results are presented in Table 4 and discussed in Example 3.
- the present invention is to methods of ameliorating or preventing apoptosis.
- the method comprises administering to a subject an amount of a therapeutically effective dioxopiperazine sufficient to prevent or delay apoptosis.
- the dioxopiperazines are not administered to ameliorate the cardiac damage caused by certain anti-neoplastic agents, but rather are administered alone or with any other, non-anti- neoplastic, or pharmaceutically acceptable substances.
- Use of the term dioxopiperazine herein refers to any of a broad range of compounds. The particular dioxopiperazine utilized will depend on the particular indication. Generally, those dioxopiperazines exhibiting anti-apoptotic activity and lacking substantial toxic side effects will be suitable for use in the present invention.
- those dioxopiperazines exhibiting pharmacologic effects similar to the bis (dioxopiperazine) s 2,3; 2,5; and 2,6 bis (dioxopiperazine) s are suitable for use in the present invention. More preferably, 2,3; 2,5; and 2,6 bis (dioxopiperazine) s are suitable for use in the present invention. Most preferably, 2,6 piperazinedione 4,4' -(1- methyl-1, 2-ethanediyl) bis-, (S) (+) [chemical formula C 11 H 16 N 4 0 4 ] is suitable for use in the present invention. In the case of 2,6 bis (dioxopiperazine) s, the ⁇ enantiomer (ICRF-187) is preferred. Also suitable for use are various pro-drugs described in U.S. Patent No. 4,755,619.
- Dioxopiperazines include a wide variety of compounds. The known therapeutic efficacy of these compounds is limited as demonstrated by the FDA approval for limited clinical use. For instance, 2,6 bis (dioxopiperazine) (dexrazoxane) and related compounds have been found to have weak anti-neoplastic effects and also to have been of use in treatment of psoriasis. For review see itiak and Wei (1988) . For descriptions of known indications and pharmaceutical compositions of dioxopiperazines see United States Patent Nos . 4,275,063; 4,755,619; 4,902,714; 5,149,710; 3,941,790; and U.K. Patent No. 1,374,979. Both neoplasias and psoriasis involve uncontrolled cellular proliferation.
- 2,6 bis (dioxopiperazine) has been found to ameliorate the cardiomyopathies associated with administration of a variety of chemotherapeutic agents. See e.g. Carlson (1992) Oncology, 6:95-100, 104, 107- 1000.
- dioxopiperazines have been found to ameliorate the cardiomyopathies associated with administration of a variety of chemotherapeutic agents. See e.g. Carlson (1992) Oncology, 6:95-100, 104, 107- 1000.
- dioxopiperazines are effective at preventing or delaying apoptosis.
- Apoptosis is a normal cellular event which can also be induced by pathological conditions and a variety of biological insults such as transient lack of oxygen, trauma, or exposure to damaging radiation.
- Enhanced apoptosis levels are involved in a wide variety of conditions including, but not limited to, cardiomyopathies, infarctions, cancer regression, immunoregulation, viral diseases, anemia, neurological disorders and neurodegenerative diseases, diarrhea and dysentery, muscular wastage, kidney failure, diabetes, hair loss, rejection of organ transplants, failure of cell transplants and prostate involution.
- cardiomyopathies are not those induced by anti-neoplastic agents, particularly those induced by anthracyclines .
- a viral disease that causes severe apoptosis is AIDS (acquired immunodeficiency syndrome) .
- the present invention is thus particularly suitable for use in the treatment of AIDS.
- dioxopiperazines that are physiologically acceptable and exert an anti-apoptotic effect are suitable for use in the present invention.
- Dioxopiperazines are said to exert an anti-apoptotic effect if they are found to do so d-n vivo and/or if they test positively in any anti-apoptosis assay.
- In vivo indicia of anti-apoptotic effects include, but are not limited to reduction of apoptotic cell death in the myocardium, brain, and kidney following either transient ischemia brought on by reduction of adequate blood perfusion or exposure to blood-borne toxic substances.
- Suitable in vitro assays include but are not limited to the assay described in co-pending United States patent application Serial No. 08/056,439 which is incorporated herein by reference. The assay is further described in the following examples.
- Dioxopiperazines are particularly useful in treating these apoptosis-associated conditions. Dioxopiperazines are also suitable for use in treating any indication previously thought to be treatable by superoxide dismutase (SOD) or antioxidant agents.
- SOD superoxide dismutase
- AMI acute myocardial infarction
- dioxopiperazines agents are effective if administered at the onset of acute ischemia, during reperfusion with oxygen-rich blood, or shortly thereafter.
- apoptotic cells are not removed from the heart as rapidly as they are from many other tissues of the body, in part because macrophages do not circulate as freely in the heart muscle tissue as they do in other parts of the body. As a result, apoptotic cells accumulate in the heart tissue and soon become a core of necrotic cells. This secondary necrosis then leads rapidly to inflammation and further damage and the heart cannot continue to function. If the heart does survive, there will be a permanent scar that will impair the ability of the heart. This secondary necrosis has now been found to occur between one and six hours following a heart attack. Dioxopiperazines are thus suitable for use in preventing this permanent impairment of heart function or cessation of heart function. The invention thus encompasses administration of therapeutically effective amounts of dioxopiperazines following a heart attack and preferably between one and six hours following a heart attack.
- the present invention is thus suitable for use in treating and thus ameliorating cardiac conditions unrelated to the cardiomyopathies caused by anti- neoplastic agents.
- cardiac conditions include, but are not limited to, development of and damage subsequent to, myocardial infarction injury or other acute events of the heart such as in post-cardiopulmonary bypass when the attempt is made to restart the heart .
- effective amounts of dioxopiperazines can be administered intravenously at the first indication of coronary arterial insufficiency often associated with onset of acute chest pain or angina pectoris.
- the dioxopiperazines may also be administered after occurrence of the infarct .
- administration of an effective amount of dioxopiperazines occurs within six hours of a heart attack. More preferably, administration occurs within one hour of a heart attack.
- Other suitable methods of administration include but are not limited to intraperitoneal and direct administration to the heart.
- dioxopiperazines Methods of administration of dioxopiperazines are known in the art and need not be described in detail .
- a therapeutically effective amount of a dioxopiperazine is suspended or solubilized in an isotonic, physiologically acceptable, sterile liquid including, but not limited to, isotonic saline.
- the dioxopiperazine is introduced by methods known in the art including but not limited to injection into a central venous line, infusion via a pump or direct intravenous injection.
- Direct administration to the heart includes but is not limited to direct intracardiac injection. Devices for such direct injection are known in the art; for instance, the Aboject cardiac syringe.
- dioxopiperazine 054 The effective concentration of dioxopiperazine will depend on the particular dioxopiperazine utilized and the method of administration. For instance/ when administered intravenously, the dioxopiperazine 054
- - 8 - concentration will be lower than when administered intracardiac.
- the total amount of dioxopiperazine administered to the patient may be greater over time when administered intravenously so as to attain an effective concentration at the site of the infarct.
- An effective concentration for amelioration of cardiotoxic side effects of various chemotherapeutics is 500- mg/m 2 2,6 bis(dioxopiperazine) ; thus this is a preferred dose.
- a broad range of doses may be effective, typically the range is from the concentration required to exert anti- apoptotic effects up to the concentration at which side effects begin to occur. Determination of the appropriate dosage is within the skill of one in the art.
- Administration of the dioxopiperazine should be maintained for a length of time effective to prevent apoptosis. Generally, apoptosis is initiated by acute lack of oxygen in the active normal myocardium. Administration of the dioxopiperazine should thus be initiated at the time of oxygen deficit or shortly thereafter. Delaying the onset of apoptosis for 24 to 72 hours will allow reperfusion of the affected myocardium to occur without concomitant cell death.
- dioxopiperazines may be administered alone or in combination with other, non-anti-neoplastic, therapeutic agents provided there are no toxic cross- reactions.
- dioxopiperazines in treating myocardial infarction, dioxopiperazines can be administered in conjunction with tissue plasminogen activator (t-PA) , urokinase, or streptokinase.
- t-PA tissue plasminogen activator
- urokinase urokinase
- streptokinase streptokinase
- dioxopiperazines may be administered in conjunction with a variety of other therapeutic agents including but not limited to, anti- inflammatory agents; anti-oxidants, SOD inhibitors, immunosuppressants, and antiviral agents.
- anti-PA tissue plasminogen activator
- SOD inhibitors anti-oxidants
- immunosuppressants immunosuppressants
- The' cells are obtained at the lowest available serial passage level preferably less than level 11.
- the phenotypic characteristics of the cells are verified as meeting the following criteria. Standard cell culture techniques are used.
- Cloning efficiency determined to be 25% ( ⁇ 2 ) at densities of 200 cells/20 cm 2 under standard growth conditions.
- Saturation cell density confirmed to be 5 x 10 5 ( ⁇ 2 x 10 5 ) cells/20 cm 2 plastic petri dish under standard growth conditions. 4. At saturation cell density, it is confirmed that more than 98% of cells are in the G_ phase of the cell cycle.
- the morphology of exponentially proliferating cultures is radically changed at saturation density such that the spindle shaped cells having extensive overlapping and lack of parallel orientation during exponential proliferation changes to wide, flat epithelioid monolayer without distinct intercellular demarcation and no overlapping.
- Cells are sensitive to malignant transformation by chemical carcinogens, typically 3- methyl cholanthrene, or ultraviolet irradiation yielding transformed foci.
- Cells do not form a fibrosarcoma tumor when injected at levels of 10 s cells subcutaneously in the suprascapular region of syngeneic animals, whereas, following malignant transformation in vi tro, tumors are observed under similar conditions. The cells are then cultured in containers that are typically 60 mm diameter plastic petri dishes specially prepared for mammalian cell culture and are commonly available from several commercial sources.
- Cells for replicate culture are obtained from stock cultures which are confirmed to be in exponential phase proliferation and not in post-confluent saturation density to ensure that cells are not arrested in the G phase of the cell cycle.
- the cells are seeded onto each plate in a volume of 5 ml complete growth medium in which are suspended a standardized number of cells.
- the standardized number should be not less than 10 3 but not greater than 10 4 cells.
- Growth medium is renewed each 48 hours.
- cell density reaches approximately 70% uniformly across each dish surface, which typically corresponds to a density of 1 x 10 s to 3 x 10 5 cells/dish, the complete growth medium is removed by aspiration and replaced with fresh serum-free growth medium.
- Drugs or agents to be assayed can be premixed into the serum-free medium, or added in appropriately small volumes immediately after the medium change.
- each agent or specific treatment is performed on at least four replicate cultures and appropriate controls are also incorporated.
- each plate is prepared for measurement of responses. The following measurements are performed:
- All non-adherent or loosely adherent cells are removed from the culture dish and measured by appropriate techniques typically counting by electric particle counting instrument. 2.
- the remaining adherent cells are exposed to a buffered (typically pH 7.3) balanced salt solution such as Hanks Balanced Salt Solution containing a standardized concentration of the enzyme trypsin.
- the trypsin concentration is typically 0.1 mg/ml but can be between 1 and 0.001 mg/ml, typically in a volume of 1 ml.
- Each culture is incubated either at ambient temperature or 37°C on a rocking platform to ensure uniform distribution of the trypsin reagent over the culture surface.
- the released cells are removed from each dish, and measured by the same means described above, typically electronic particle counting. This measurement is referred to as the serum deprivation release or SDR count and typically contains at least 98% apoptotic cells.
- SDR count serum deprivation release
- the remaining adherent cells in each dish are then released by exposure to a buffered solution containing a calcium ion chelating agent typically EDTA typically at a concentration of 2 mg/ml.
- This measurement is referred to as the proteinase sensitive or PS count and typically contains the cells that would have otherwise died by apoptosis in the absence o-f an effective inhibitor.
- the final cells remaining adhered to the solid support are then immediately dispersed and removed from the dish for measurement by the same means used in previous measurements, typically electronic particle counting.
- This measurement is referred to as the proteinase resistant or PR count and typically contains cells that express the property of resistance to proteinase-induced shape change which has been identified to be a critical specific expression related to control of apoptosis.
- Each cell count is typically performed in duplicate on each of four replicate dishes for each experimental treatment group and control.
- a preferred positive result is typically dependent upon a statistically significant reduction of SDR cells in combination with a statistically significant increase in PR cells.
- putative apoptosis modulating agents can produce either reduction of SDR cells or increased PR cells and should be considered to be positive and warranting further consideration.
- Agents that produce either increased SDR or decreased total cell counts i.e., SDR + PS + PR should be considered to be potentially cytotoxic at the concentrations applied.
- a negative outcome would be failure to observe changes in either SDR or PR counts at concentrations determined to be non-toxic.
- Example 2 Bovine Serum Screening Test The purpose of screening the bovine serum used as a supplement to the synthetic portion of the cell culture growth medium is to determine the best manufacturer's production batch in terms of optimal assay performance. This aspect of the assay is counter ⁇ intuitive in as much as conventional serum screening tests used by those skilled in the art are based primarily on determining the relative ability of various production batches of animal sera to maintain high viability or survival rates of various reference cell cultures. Contrary to that rationale, the apoptosis assay serum screening test determines the relative ability of various serum production batches to yield apoptotic, or dying and dead, cells upon withdrawal from the growth medium.
- Tables 1 and 2 present typical data obtained in the process of screening 5 different bovine serum production batches obtained from a commercial source. These are listed as Lots 1 through 5.
- cells are treated with TPA.
- Two independent variables to be measured are the number of apoptotic " cells in the untreated control cultures compared with replicate cultures treated with TPA. These variables are the released cell or Apoptotic count, and the proteinase- resistant or PR cell count as shown in Table 1. Results were evaluated as follows: Apoptotic and PR responses are expressed in terms of a ratio or percentage of the corresponding response obtained in untreated replicate cultures. A desirable response would be simultaneous maximal reduction of Apoptotic cell count and enhancement of PR cell count. Therefore, the responses are then ranked according to each lot's respective response for each variable as shown in Table 2.
- Example 3 Dioxopiperazine Anti-apoptosis Assay Utilizing the methods described in Examples 1 and 2, the dioxopiperazine, 2,6 piperazinedione 4,4' -(1- methyl-1, 2-ethanediyl) bis-, (S) (+) was tested in the C3H-10T ⁇ assay to determine the anti-apoptosis activity. The assay was performed as described above with the concentrations of dioxopiperazine indicated in Tables 3 and 4. The results obtained are presented in Tables 3 and 4; and Figure 1.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU73705/94A AU7370594A (en) | 1993-07-23 | 1994-07-22 | Methods of treating apoptosis and associated conditions |
JP7505327A JPH09503749A (en) | 1993-07-23 | 1994-07-22 | Methods of treating apoptosis and related conditions |
EP94922680A EP0711168A4 (en) | 1993-07-23 | 1994-07-22 | Methods of treating apoptosis and associated conditions |
KR1019960700340A KR960703597A (en) | 1993-07-23 | 1994-07-22 | METHODS OF TREATING APOPTOSIS AND ASSOCIATED CONDITIONS |
BR9407145A BR9407145A (en) | 1993-07-23 | 1994-07-22 | Methods to treat apoptosis and associated conditions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9678893A | 1993-07-23 | 1993-07-23 | |
US08/096,788 | 1993-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995003054A1 true WO1995003054A1 (en) | 1995-02-02 |
Family
ID=22259083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/008268 WO1995003054A1 (en) | 1993-07-23 | 1994-07-22 | Methods of treating apoptosis and associated conditions |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0711168A4 (en) |
JP (1) | JPH09503749A (en) |
KR (1) | KR960703597A (en) |
AU (1) | AU7370594A (en) |
BR (1) | BR9407145A (en) |
CA (1) | CA2167805A1 (en) |
WO (1) | WO1995003054A1 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6106830A (en) * | 1996-08-29 | 2000-08-22 | Tobishi Pharmaceutical Co., Ltd. | Methods for the treatment of apoptosis-related diseases by batroxobin |
WO2001019358A2 (en) * | 1999-09-10 | 2001-03-22 | Cyathus Exquirere Pharmaforschungs Gmbh | Use dexrazoxane for treating psoriasis |
WO2001037836A1 (en) * | 1999-11-24 | 2001-05-31 | Emory University | Diimino-piperazine derivatives for use as modulators of cell regulation |
US6552025B1 (en) | 1999-11-24 | 2003-04-22 | Emory University | Diimino-piperazine derivatives for use as modulators of cell regulation |
US6693100B1 (en) | 1999-09-10 | 2004-02-17 | Iervant Zarmanian | Pharmaceutical compositions for treating psoriasis |
WO2005000311A1 (en) * | 2003-06-24 | 2005-01-06 | Glaxo Group Limited | Substituted diketopiperazines for the treatment of benign prostatic hyperplasia |
EP1622633A2 (en) * | 2003-05-15 | 2006-02-08 | DMI Biosciences, Inc. | Treatment of t-cell mediated diseases |
WO2008021250A2 (en) * | 2006-08-10 | 2008-02-21 | Fred Hutchinson Cancer Research Center | Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins |
US8841307B2 (en) | 2000-08-04 | 2014-09-23 | Ampio Pharmaceuticals, Inc. | Method of using diketopiperazines and composition containing them |
US8871772B2 (en) | 2008-05-27 | 2014-10-28 | Ampio Pharmaceuticals, Inc. | Therapeutic methods and compounds |
US8980834B2 (en) | 2011-10-10 | 2015-03-17 | Ampio Pharmaceuticals, Inc. | Treatment of degenerative joint disease |
US9034878B2 (en) | 2010-09-07 | 2015-05-19 | Ampio Pharmaceuticals, Inc. | Treatment of diseases |
US9808454B2 (en) | 2013-03-15 | 2017-11-07 | Ampio Pharmaceuticals, Inc. | Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same |
US9925300B2 (en) | 2011-10-10 | 2018-03-27 | Ampio Pharmaceuticals, Inc. | Implantable medical devices with increased immune tolerance, and methods for making and implanting |
US9956217B2 (en) | 2014-08-18 | 2018-05-01 | Ampio Pharmaceuticals, Inc. | Treatment of joint conditions |
US10881710B2 (en) | 2011-10-28 | 2021-01-05 | Ampio Pharmaceuticals, Inc. | Treatment of rhinitis |
US11389512B2 (en) | 2015-06-22 | 2022-07-19 | Ampio Pharmaceuticals, Inc. | Use of low molecular weight fractions of human serum albumin in treating diseases |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007523858A (en) * | 2003-06-24 | 2007-08-23 | ユニバーシティ オブ コネチカット | Methods for inhibiting vascular permeability and apoptosis |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991000729A2 (en) * | 1989-07-13 | 1991-01-24 | National Research Development Corporation | Bis-dioxopiperazines, and their use as protecting agents |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9024861D0 (en) * | 1990-11-15 | 1991-01-02 | Hellmann Kurt | Bis-dioxopiperazines for treating liver tumors |
-
1994
- 1994-07-22 WO PCT/US1994/008268 patent/WO1995003054A1/en not_active Application Discontinuation
- 1994-07-22 JP JP7505327A patent/JPH09503749A/en active Pending
- 1994-07-22 AU AU73705/94A patent/AU7370594A/en not_active Abandoned
- 1994-07-22 BR BR9407145A patent/BR9407145A/en not_active Application Discontinuation
- 1994-07-22 EP EP94922680A patent/EP0711168A4/en not_active Withdrawn
- 1994-07-22 CA CA002167805A patent/CA2167805A1/en not_active Abandoned
- 1994-07-22 KR KR1019960700340A patent/KR960703597A/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991000729A2 (en) * | 1989-07-13 | 1991-01-24 | National Research Development Corporation | Bis-dioxopiperazines, and their use as protecting agents |
Non-Patent Citations (2)
Title |
---|
ONCOLOGY, Volume 6, No. 6, issued June 1992, (California, US), R.W. CARLSON: "Reducing the Cardiotoxicity of the Anthracyclines", pages 95-100, see the entire document. * |
See also references of EP0711168A4 * |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6106830A (en) * | 1996-08-29 | 2000-08-22 | Tobishi Pharmaceutical Co., Ltd. | Methods for the treatment of apoptosis-related diseases by batroxobin |
US6399576B1 (en) | 1996-08-29 | 2002-06-04 | Tobishi Pharmaceutical Co., Ltd. | Method of inhibiting apoptosis |
WO2001019358A2 (en) * | 1999-09-10 | 2001-03-22 | Cyathus Exquirere Pharmaforschungs Gmbh | Use dexrazoxane for treating psoriasis |
WO2001019358A3 (en) * | 1999-09-10 | 2001-10-04 | Cyathus Exquirere Pharmaforsch | Use dexrazoxane for treating psoriasis |
US6693100B1 (en) | 1999-09-10 | 2004-02-17 | Iervant Zarmanian | Pharmaceutical compositions for treating psoriasis |
WO2001037836A1 (en) * | 1999-11-24 | 2001-05-31 | Emory University | Diimino-piperazine derivatives for use as modulators of cell regulation |
US6552025B1 (en) | 1999-11-24 | 2003-04-22 | Emory University | Diimino-piperazine derivatives for use as modulators of cell regulation |
US6750211B2 (en) | 1999-11-24 | 2004-06-15 | Emory University | Diimino compounds for use as modulators of cell regulation |
US8841307B2 (en) | 2000-08-04 | 2014-09-23 | Ampio Pharmaceuticals, Inc. | Method of using diketopiperazines and composition containing them |
US8916568B2 (en) | 2000-08-04 | 2014-12-23 | Ampio Pharmaceuticals, Inc. | Method of using diketopiperazines and composition containing them |
US10039760B2 (en) | 2000-08-04 | 2018-08-07 | Ampio Pharmaceuticals, Inc. | Method of using diketopiperazines and composition containing them |
US9561226B2 (en) | 2000-08-04 | 2017-02-07 | Ampio Pharmaceuticals, Inc. | Method of using diketopiperazines and composition containing them |
CN103142599A (en) * | 2003-05-15 | 2013-06-12 | Dmi生物科学公司 | Treatment of T-cell mediated diseases |
US10828296B2 (en) | 2003-05-15 | 2020-11-10 | Ampio Pharmaceuticals, Inc. | Treatment of T-cell mediated diseases |
US9730924B2 (en) | 2003-05-15 | 2017-08-15 | Ampio Pharmaceuticals, Inc. | Treatment of T-cell mediated diseases |
CN104095851A (en) * | 2003-05-15 | 2014-10-15 | 安皮奥制药股份有限公司 | Treatment of T-cell mediated diseases |
US9707227B2 (en) | 2003-05-15 | 2017-07-18 | Ampio Pharmaceuticals, Inc. | Treatment of T-cell mediated diseases |
EP1622633A4 (en) * | 2003-05-15 | 2010-02-17 | Dmi Biosciences Inc | Treatment of t-cell mediated diseases |
US8962568B2 (en) | 2003-05-15 | 2015-02-24 | Ampio Pharmaceuticals, Inc. | Treatment of T-cell mediated diseases |
US8969308B2 (en) | 2003-05-15 | 2015-03-03 | Ampio Pharmaceuticals, Inc. | Treatment of T-cell mediated diseases |
US11369598B2 (en) | 2003-05-15 | 2022-06-28 | Ampio Pharmaceuticals, Inc. | Treatment of T-cell mediated diseases |
CN102727861B (en) * | 2003-05-15 | 2015-05-13 | 安皮奥制药股份有限公司 | Treatment of t-cell mediated diseases |
EP1622633A2 (en) * | 2003-05-15 | 2006-02-08 | DMI Biosciences, Inc. | Treatment of t-cell mediated diseases |
WO2005000311A1 (en) * | 2003-06-24 | 2005-01-06 | Glaxo Group Limited | Substituted diketopiperazines for the treatment of benign prostatic hyperplasia |
WO2008021250A3 (en) * | 2006-08-10 | 2009-04-02 | Hutchinson Fred Cancer Res | Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins |
WO2008021250A2 (en) * | 2006-08-10 | 2008-02-21 | Fred Hutchinson Cancer Research Center | Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins |
US9522893B2 (en) | 2008-05-27 | 2016-12-20 | Ampio Pharmaceuticals, Inc. | Therapeutic methods and compounds |
US8871772B2 (en) | 2008-05-27 | 2014-10-28 | Ampio Pharmaceuticals, Inc. | Therapeutic methods and compounds |
US9034878B2 (en) | 2010-09-07 | 2015-05-19 | Ampio Pharmaceuticals, Inc. | Treatment of diseases |
US10471178B2 (en) | 2011-10-10 | 2019-11-12 | Ampio Pharmaceuticals, Inc. | Implantable medical devices with increased immune tolerance, and methods for making and implanting |
US10842847B2 (en) | 2011-10-10 | 2020-11-24 | Ampio Pharmaceuticals, Inc. | Treatment of degenerative joint disease |
US8980834B2 (en) | 2011-10-10 | 2015-03-17 | Ampio Pharmaceuticals, Inc. | Treatment of degenerative joint disease |
US9623072B2 (en) | 2011-10-10 | 2017-04-18 | Ampio Pharmaceuticals, Inc. | Treatment of degenerative joint disease |
US10251930B2 (en) | 2011-10-10 | 2019-04-09 | Ampio Pharmaceuticals, Inc. | Treatment of degenerative joint disease |
US11058798B2 (en) | 2011-10-10 | 2021-07-13 | Ampio Pharmaceuticals, Inc. | Implantable medical devices with increased immune tolerance, and methods for making and implanting |
US9925300B2 (en) | 2011-10-10 | 2018-03-27 | Ampio Pharmaceuticals, Inc. | Implantable medical devices with increased immune tolerance, and methods for making and implanting |
US9060968B2 (en) | 2011-10-10 | 2015-06-23 | Ampio Pharmaceuticals, Inc. | Treatment of degenerative joint disease |
US10881710B2 (en) | 2011-10-28 | 2021-01-05 | Ampio Pharmaceuticals, Inc. | Treatment of rhinitis |
US9808454B2 (en) | 2013-03-15 | 2017-11-07 | Ampio Pharmaceuticals, Inc. | Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same |
US11026940B2 (en) | 2013-03-15 | 2021-06-08 | Ampio Pharmaceuticals, Inc. | Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same |
US10342793B2 (en) | 2014-08-18 | 2019-07-09 | Ampio Pharmaceuticals, Inc. | Treatment of joint conditions |
US11090301B2 (en) | 2014-08-18 | 2021-08-17 | Ampio Pharmaceuticals, Inc. | Treatment of joint conditions |
US9956217B2 (en) | 2014-08-18 | 2018-05-01 | Ampio Pharmaceuticals, Inc. | Treatment of joint conditions |
US11389512B2 (en) | 2015-06-22 | 2022-07-19 | Ampio Pharmaceuticals, Inc. | Use of low molecular weight fractions of human serum albumin in treating diseases |
Also Published As
Publication number | Publication date |
---|---|
KR960703597A (en) | 1996-08-31 |
EP0711168A4 (en) | 1998-04-01 |
BR9407145A (en) | 1996-09-17 |
CA2167805A1 (en) | 1995-02-02 |
EP0711168A1 (en) | 1996-05-15 |
JPH09503749A (en) | 1997-04-15 |
AU7370594A (en) | 1995-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995003054A1 (en) | Methods of treating apoptosis and associated conditions | |
Hauser et al. | Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. | |
Kumar et al. | Apoptosis in adriamycin cardiomyopathy and its modulation by probucol | |
Mgbonyebi et al. | Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells | |
CN101242817B (en) | HIF1 alpha modulators purposes in treatment cancer | |
Lewis et al. | Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation | |
EP0196415B1 (en) | Trichostatins a and c as antitumour drugs | |
CN1997622B (en) | Polycationic compounds and uses thereof | |
Dusenbery et al. | Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia | |
KR100518106B1 (en) | Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies | |
Hoshino et al. | Review of basic concepts of cell kinetics as applied to brain tumors | |
Zhang et al. | Genistein inhibit cytokines or growth factor-induced proliferation and transformation phenotype in fibroblast-like synoviocytes of rheumatoid arthritis | |
Feng et al. | Tamoxifen-induced apoptosis of rat C6 glioma cells via PI3K/Akt, JNK and ERK activation | |
Verdoorn et al. | Cellular migration, proliferation, and contraction: an in vitro approach to a clinical problem proliferative vitreoretinopathy | |
KANG et al. | In vitro evaluation of antiproliferative potential of calcium channel blockers in human Tenon's fibroblasts | |
Recine et al. | Combined modality therapy for locally advanced non‐small cell lung carcinoma | |
CN111658655A (en) | Application of cucurbitacin B in preparation of iron death inducer and anti-nasopharyngeal carcinoma drug | |
Li et al. | Bryostatin 1 (bryo1)-induced monocytic differentiation in THP-1 human leukemia cells is associated with enhanced c-fyn tyrosine kinase and M-CSF receptors | |
Tonn et al. | Differential effects of vincristine and phenytoin on the proliferation, migration, and invasion of human glioma cell lines | |
Levine et al. | Megakaryocyte interaction with subendothelial extracellular matrix is associated with adhesion, platelet-like shape change, and thromboxane A2 production | |
CN110652515A (en) | Application of AMPK inhibitor Compound C in tumor treatment drug | |
Cai et al. | Transforming growth factor-beta differentially regulates the adhesiveness of normal and psoriatic dermal microvascular endothelial cells for peripheral blood mononuclear cells | |
Cortesina et al. | The effect of preoperative local interleukin-2 (IL-2) injections in patients with head and neck squamous cell carcinoma: An immunological study | |
LoBue | Humoral Control of Growth And Differentiation: Vertebrate Regulatory Factors | |
Chou et al. | Stimulation of plasminogen activator expression and induction of DNA synthesis by microtubule-disruptive drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2167805 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994922680 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1994922680 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1996 586863 Country of ref document: US Date of ref document: 19960805 Kind code of ref document: A |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994922680 Country of ref document: EP |